Reviva Q2 net loss narrows to $2.4M; cash $19.9M; brilaroxazine patent extension pursued

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss $2.4M ($0.19/share) for Q2 2026 vs $6.1M ($2.40/share) year ago; per-share reflects 1:20 reverse split.
Cash and equivalents $19.9M at June 30, 2026 vs $14.4M at Dec 31, 2025.
Filed US composition-of-matter patent for new brilaroxazine form to extend exclusivity through 2046.
FDA feedback on using new formulation in RECOVER-2 trial and NDA expected Q4 2026; bioequivalence study planned Q4 2026.
Patient enrollment in RECOVER-2 Phase 3 trial expected 1H 2027, subject to additional financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.